Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies

Tracey M. Farragher, Mark Lunt, Darren Plant, Diane K. Bunn, Anne Barton, Deborah P. M. Symmons

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)


Objective To compare the clinical utility of anti–cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF) testing in predicting both functional outcome and response to treatment in early inflammatory polyarthritis (IP) patients. Methods A total of 916 IP subjects from a primary care incidence registry (1990–1994) had anti-CCP antibody and RF status determined at baseline. Mean change in Health Assessment Questionnaire (HAQ) score between baseline and 5 years was compared by antibody status. The effect of treatment with disease-modifying antirheumatic drugs and/or steroids over 5 years, early (
Original languageEnglish
Pages (from-to)664-675
Number of pages12
JournalArthritis Care & Research
Issue number5
Publication statusPublished - May 2010

Cite this